Birchview Capital as of Sept. 30, 2024
Portfolio Holdings for Birchview Capital
Birchview Capital holds 61 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bristol Myers Squibb (BMY) | 30.8 | $36M | 686k | 51.74 | |
| Biodesix (BDSX) | 8.6 | $9.9M | 5.5M | 1.78 | |
| ACADIA Pharmaceuticals (ACAD) | 5.3 | $6.2M | 400k | 15.38 | |
| Aziyo Biologics (ELUT) | 4.4 | $5.0M | 1.3M | 3.81 | |
| United Therapeutics Corporation (UTHR) | 3.1 | $3.6M | 10k | 358.35 | |
| Prothena Corp SHS (PRTA) | 3.0 | $3.5M | 210k | 16.73 | |
| Neurocrine Biosciences (NBIX) | 3.0 | $3.5M | 30k | 115.22 | |
| Corcept Therapeutics Incorporated (CORT) | 3.0 | $3.4M | 74k | 46.28 | |
| Harrow Health (HROW) | 2.8 | $3.3M | 73k | 44.96 | |
| Quidel Corporation | 2.7 | $3.1M | 68k | 45.60 | |
| Foghorn Therapeutics (FHTX) | 2.6 | $3.0M | 321k | 9.31 | |
| Axogen (AXGN) | 2.4 | $2.8M | 197k | 14.02 | |
| Phreesia (PHR) | 2.3 | $2.6M | 115k | 22.79 | |
| Stoke Therapeutics (STOK) | 2.2 | $2.6M | 210k | 12.29 | |
| Protagonist Therapeutics (PTGX) | 1.9 | $2.2M | 48k | 45.00 | |
| Travere Therapeutics (TVTX) | 1.8 | $2.1M | 148k | 13.99 | |
| Masimo Corporation (MASI) | 1.8 | $2.0M | 15k | 133.33 | |
| Encana Corporation (OVV) | 1.7 | $2.0M | 52k | 38.31 | |
| Docgo (DCGO) | 1.5 | $1.7M | 515k | 3.32 | |
| Castle Biosciences (CSTL) | 1.4 | $1.7M | 58k | 28.52 | |
| Alkermes SHS (ALKS) | 1.2 | $1.4M | 50k | 27.99 | |
| EQT Corporation (EQT) | 1.1 | $1.3M | 35k | 36.64 | |
| Alphatec Holdings (ATEC) | 1.0 | $1.1M | 198k | 5.56 | |
| Kalvista Pharmaceuticals (KALV) | 0.8 | $950k | 82k | 11.58 | |
| Kiniksa Pharmaceuticals | 0.7 | $750k | 30k | 24.99 | |
| 10x Genomics Cl A Com (TXG) | 0.6 | $677k | 30k | 22.58 | |
| Halozyme Therapeutics (HALO) | 0.5 | $572k | 10k | 57.24 | |
| Accelr8 Technology | 0.5 | $556k | 325k | 1.71 | |
| Cytokinetics (CYTK) | 0.5 | $528k | 10k | 52.80 | |
| Inhibrx Biosciences (INBX) | 0.4 | $503k | 32k | 15.66 | |
| Keros Therapeutics (KROS) | 0.4 | $407k | 7.0k | 58.07 | |
| Apellis Pharmaceuticals (APLS) | 0.4 | $404k | 14k | 28.84 | |
| Treace Med Concepts (TMCI) | 0.3 | $396k | 68k | 5.80 | |
| Xenon Pharmaceuticals (XENE) | 0.3 | $394k | 10k | 39.37 | |
| Karyopharm Therapeutics | 0.3 | $390k | 470k | 0.83 | |
| Coherus Biosciences (CHRS) | 0.3 | $387k | 372k | 1.04 | |
| Arvinas Ord (ARVN) | 0.3 | $370k | 15k | 24.63 | |
| Progyny (PGNY) | 0.3 | $369k | 22k | 16.76 | |
| Biohaven Pharmaceutical Holding | 0.3 | $368k | 7.4k | 49.97 | |
| Axsome Therapeutics (AXSM) | 0.3 | $360k | 4.0k | 89.87 | |
| Cullinan Oncology (CGEM) | 0.3 | $335k | 20k | 16.74 | |
| Wave Life Sciences SHS (WVE) | 0.3 | $328k | 40k | 8.20 | |
| Springworks Therapeutics (SWTX) | 0.3 | $320k | 10k | 32.04 | |
| Novocure Ord Shs (NVCR) | 0.3 | $313k | 20k | 15.63 | |
| Sarepta Therapeutics (SRPT) | 0.3 | $312k | 2.5k | 124.89 | |
| BioCryst Pharmaceuticals (BCRX) | 0.3 | $304k | 40k | 7.60 | |
| Amicus Therapeutics (FOLD) | 0.3 | $299k | 28k | 10.68 | |
| Blueprint Medicines (BPMC) | 0.2 | $250k | 2.7k | 92.50 | |
| Xencor (XNCR) | 0.2 | $247k | 12k | 20.11 | |
| Gossamer Bio (GOSS) | 0.1 | $136k | 138k | 0.99 | |
| Bluebird Bio | 0.1 | $110k | 211k | 0.52 | |
| Alumis (ALMS) | 0.1 | $107k | 10k | 10.68 | |
| Liquidia Technologies (LQDA) | 0.1 | $100k | 10k | 10.00 | |
| Uniqure Nv SHS (QURE) | 0.1 | $99k | 20k | 4.93 | |
| Inflarx Nv (IFRX) | 0.1 | $77k | 50k | 1.53 | |
| 2seventy Bio | 0.1 | $75k | 16k | 4.72 | |
| Ventyx Biosciences (VTYX) | 0.1 | $63k | 29k | 2.18 | |
| Zentalis Pharmaceuticals (ZNTL) | 0.1 | $59k | 16k | 3.68 | |
| Cabaletta Bio (CABA) | 0.0 | $47k | 10k | 4.72 | |
| Outset Med | 0.0 | $6.8k | 10k | 0.68 | |
| Cero Therapeutics Holdings Class A Com | 0.0 | $1.2k | 13k | 0.09 |
